CSIMarket
 


Harrow Inc   (HROW)
Other Ticker:  
 
 

HROW's Capital Expenditures Growth by Quarter and Year

Harrow Inc 's Capital Expenditures results by quarter and year




HROW Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 1.04 0.15 0.10
III Quarter September 0.52 1.07 0.34 0.28
II Quarter June 0.25 0.26 1.16 0.34
I Quarter March 0.50 0.41 0.22 0.27
FY   1.27 2.78 1.87 0.99



HROW Capital Expenditures third quarter 2023 Y/Y Growth Comment
Harrow Inc reported drop in Capital Expenditures in the third quarter 2023 by -51.4% to $ 0.52 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Harrow Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 513.18%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 121 other companies have achieved higher Capital Expenditures growth. While Harrow Inc ' s Capital Expenditures meltdown of -51.4% ranks overall at the positon no. 2450 in the third quarter 2023.




HROW Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 593.33 % 50 % -89.69 %
III Quarter September -51.4 % 214.71 % 21.43 % 250 %
II Quarter June -3.85 % -77.59 % 241.18 % -26.09 %
I Quarter March 21.95 % 86.36 % -18.52 % -18.18 %
FY   - 48.66 % 88.89 % -46.2 %

Financial Statements
Harrow Inc 's third quarter 2023 Capital Expenditures $ 0.52 millions HROW's Income Statement
Harrow Inc 's third quarter 2022 Capital Expenditures $ 1.07 millions Quarterly HROW's Income Statement
New: More HROW's historic Capital Expenditures Growth >>


HROW Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -2.8 % -55.88 % -64.29 %
III Quarter September 108 % 311.54 % -70.69 % -17.65 %
II Quarter June -50 % -36.59 % 427.27 % 25.93 %
I Quarter March -51.92 % 173.33 % 120 % -72.16 %
FY (Year on Year)   - 48.66 % 88.89 % -46.2 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #122
Healthcare Sector #359
Overall #2450

Capital Expenditures Y/Y Growth Statistics
High Average Low
8553.57 % 513.18 % -92.8 %
(Mar 31 2016)   (Jun 30 2017)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #122
Healthcare Sector #359
Overall #2450
Capital Expenditures Y/Y Growth Statistics
High Average Low
8553.57 % 513.18 % -92.8 %
(Mar 31 2016)   (Jun 30 2017)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Harrow Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1480.46 % 96.81 % -100 %
(Sep 30 2014)  


HROW's III. Quarter Q/Q Capital Expenditures Comment
Harrow Inc achieved in the III. Quarter 2023 above company average sequential Capital Expenditures doubling of 108%, to $ 0.52 millions, from $0.25 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Harrow Inc 's Capital Expenditures growth quarter on quarter, overall rank is 383.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #91
Overall #383
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #91
Overall #383
Capital Expenditures Q/Q Growth Statistics
High Average Low
1480.46 % 96.81 % -100 %
(Sep 30 2014)  


HROW's III. Quarter Q/Q Capital Expenditures Comment
Harrow Inc achieved in the III. Quarter 2023 above company average sequential Capital Expenditures doubling of 108%, to $ 0.52 millions, from $0.25 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Harrow Inc 's Capital Expenditures growth quarter on quarter, overall rank is 383.


Harrow Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 2.30 $ 2.85 $ 2.86 $ 2.77 $ 1.88
Y / Y Capital Expenditures Growth (TTM) 22.13 % 146.33 % 39.06 % 48.29 % 3.12 %
Year on Year Capital Expenditures Growth Overall Ranking # 1286 # 1601 # 227 # 449 # 1545
Seqeuential Capital Expenditures Change (TTM) -19.26 % -0.31 % 3.1 % 47.19 % 62.83 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 406 # 1968 # 1209 # 1601 # 181




Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep 30 2023 period, Harrow Inc 's cumulative twelve months Capital Expenditures were $ 2 millions, company would post below average annual Capital Expenditures growth of 62.83% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Harrow Inc 's Capital Expenditures growth from the 0.25% growth in Jun 30 2023.

In the Healthcare sector 171 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1286, from total ranking in previous quarter at 1601.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
2033.87 %
197.68 %
-85.66 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 29
Healthcare Sector # 172
Overall # 1286

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
2033.87 %
197.68 %
-85.66 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 75
S&P 500 # 406
Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep 30 2023 period, Harrow Inc 's cumulative twelve months Capital Expenditures were $ 2 millions, company would post below average annual Capital Expenditures growth of -85.66% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Harrow Inc 's Capital Expenditures growth from the 0.25% growth in Jun 30 2023.

In the Healthcare sector 171 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1286, from total ranking in previous quarter at 1601.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
2033.87 %
197.68 %
-85.66 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 29
Healthcare Sector # 172
Overall # 1286

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
2033.87 %
197.68 %
-85.66 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 75
S&P 500 # 406




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
HROW's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for HROW's Competitors
Capital Expenditures Growth for Harrow Inc 's Suppliers
Capital Expenditures Growth for HROW's Customers

You may also want to know
HROW's Annual Growth Rates HROW's Profitability Ratios HROW's Asset Turnover Ratio HROW's Dividend Growth
HROW's Roe HROW's Valuation Ratios HROW's Financial Strength Ratios HROW's Dividend Payout Ratio
HROW's Roa HROW's Inventory Turnover Ratio HROW's Growth Rates HROW's Dividend Comparisons



Companies with similar Capital Expenditures doubling for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com